Stay updated with breaking news from Recode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Plus Smoothie King CEO launches new Asian concept; Rosewood Property Company and Champion Partners started construction on South Dallas industrial; and more.
Plus: BioLabs announces two inaugural tenants and outlines future plans; Park Place Dealerships to give away $100,000 to local nonprofits; and more.
ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors. The startup’s technology uses lipid nanoparticles to deliver genetic medicines, and its two lead programs are for rare lung disorders.
ReCode Therapeutics is back with its second $80 million financing round, this time a series B from Pfizer, Sanofi and VC shops, to bring its lead programs into human trials. Up first are cystic fibrosis and primary ciliary dyskinesia, another lung disease.
Here, in our final post, we provide an analysis of the current landscape and offer conclusions. Moderna, BioNTech and CureVac –Leading Pioneers The three largest and best-positioned players in the mRNA space are currently Moderna, BioNTech and CureVac, each having very large patent estates, 11-figure market caps, double-digit candidates in their pipelines, years of development work and accumulated know-how under their belts, and key licenses and other strategic alliances in place for the manufacture, development, and commercialization of mRNA-based products. Moderna and BioNTech (with Pfize...